{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:51:47Z","timestamp":1789987907379,"version":"4.0.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["N01 MH 90001"],"award-info":[{"award-number":["N01 MH 90001"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.schres.2008.10.011","type":"journal-article","created":{"date-parts":[[2008,11,22]],"date-time":"2008-11-22T05:39:05Z","timestamp":1227332345000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["Results of phase 3 of the CATIE schizophrenia trial"],"prefix":"10.1016","volume":"107","author":[{"given":"T. Scott","family":"Stroup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"McEvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin S.","family":"Swartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.E.","family":"Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Rosenheck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.schres.2008.10.011_bib1","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.4088\/JCP.v68n1107","article-title":"Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials","volume":"68","author":"Bushe","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2008.10.011_bib2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","article-title":"Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials","volume":"158","author":"Chakos","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2008.10.011_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/oxfordjournals.schbul.a006993","article-title":"Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies","volume":"29","author":"Davis","year":"2003","journal-title":"Schizophr. Bull."},{"issue":"10","key":"10.1016\/j.schres.2008.10.011_bib4","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"9618","key":"10.1016\/j.schres.2008.10.011_bib5","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.schres.2008.10.011_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.schbul.a006990","article-title":"Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale","volume":"29","author":"Keefe","year":"2003","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2008.10.011_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/oxfordjournals.schbul.a007071","article-title":"The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003","volume":"30","author":"Lehman","year":"2004","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2008.10.011_bib8","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/schbul\/sbj067","article-title":"Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia","volume":"32","author":"Lewis","year":"2006","journal-title":"Schizophr. Bull."},{"issue":"12","key":"10.1016\/j.schres.2008.10.011_bib9","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.schres.2008.10.011_bib10","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2008.10.011_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2008.10.011_bib12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2008.10.011_bib13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1176\/ajp.2007.164.3.415","article-title":"Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study","volume":"164","author":"Stroup","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2008.10.011_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/oxfordjournals.schbul.a006989","article-title":"Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial","volume":"29","author":"Swartz","year":"2003","journal-title":"Schizophr. Bull."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996408004726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996408004726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:22:13Z","timestamp":1760296933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996408004726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0920996408004726"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2008.10.011","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of phase 3 of the CATIE schizophrenia trial","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2008.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier B.V. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}